Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society Symposium
Artelo Biosciences (Nasdaq: ARTL) presented positive preclinical data for its lead FABP5 inhibitor ART26.12 at the 35th Annual International Cannabinoid Research Society Symposium. The study demonstrated that ART26.12, a first-in-class, non-opioid, non-steroidal analgesic drug candidate, effectively reduced osteoarthritis pain in preclinical models.
Key findings showed that ART26.12's efficacy matched naproxen, a common NSAID, while maintaining effectiveness throughout a four-week chronic dosing period without developing tolerance. The drug increased plasma levels of endocannabinoids 2-AG and OEA, correlating with improved weight-bearing ability in affected limbs. Importantly, ART26.12 may offer safety advantages over NSAIDs, which typically cause gastrointestinal side effects in one-third of patients and increase gastric ulcer risks five-fold.
[ "Drug candidate ART26.12 showed efficacy comparable to naproxen in treating osteoarthritis pain", "No tolerance development observed during four-week chronic dosing period", "Potential safety advantages over NSAIDs, which typically cause side effects in 33% of patients", "Demonstrated direct effect on relevant endocannabinoid plasma levels" ]Artelo Biosciences (Nasdaq: ARTL) ha presentato dati preclinici positivi per il suo principale inibitore FABP5, ART26.12, al 35掳 Simposio Annuale Internazionale della Societ脿 di Ricerca sui Cannabinoidi. Lo studio ha dimostrato che ART26.12, un candidato farmaco analgesico di prima classe, non oppioide e non steroideo, riduce efficacemente il dolore da osteoartrite nei modelli preclinici.
I risultati chiave hanno evidenziato che l鈥檈fficacia di ART26.12 猫 paragonabile a quella del naprossene, un comune FANS, mantenendo l鈥檈fficacia per tutto il periodo di somministrazione cronica di quattro settimane senza sviluppare tolleranza. Il farmaco ha aumentato i livelli plasmatici degli endocannabinoidi 2-AG e OEA, correlati a un miglioramento della capacit脿 di carico degli arti interessati. Importante, ART26.12 potrebbe offrire vantaggi di sicurezza rispetto ai FANS, che solitamente provocano effetti gastrointestinali in un terzo dei pazienti e aumentano di cinque volte il rischio di ulcere gastriche.
- Il candidato farmaco ART26.12 ha mostrato un鈥檈fficacia paragonabile al naprossene nel trattamento del dolore da osteoartrite
- Non 猫 stata osservata tolleranza durante il periodo di somministrazione cronica di quattro settimane
- Potenziali vantaggi di sicurezza rispetto ai FANS, che causano effetti collaterali nel 33% dei pazienti
- Effetto diretto dimostrato sui livelli plasmatici degli endocannabinoidi rilevanti
Artelo Biosciences (Nasdaq: ARTL) present贸 datos precl铆nicos positivos para su principal inhibidor de FABP5, ART26.12, en el 35潞 Simposio Anual Internacional de la Sociedad de Investigaci贸n sobre Cannabinoides. El estudio demostr贸 que ART26.12, un candidato a f谩rmaco analg茅sico de primera clase, no opioide y no esteroideo, redujo eficazmente el dolor de la osteoartritis en modelos precl铆nicos.
Los hallazgos clave mostraron que la eficacia de ART26.12 fue comparable a la del naproxeno, un AINE com煤n, manteniendo la efectividad durante un per铆odo de dosificaci贸n cr贸nica de cuatro semanas sin desarrollar tolerancia. El f谩rmaco aument贸 los niveles plasm谩ticos de endocannabinoides 2-AG y OEA, lo que se correlacion贸 con una mejor capacidad de carga en las extremidades afectadas. Es importante destacar que ART26.12 podr铆a ofrecer ventajas de seguridad sobre los AINE, que normalmente causan efectos gastrointestinales en un tercio de los pacientes y aumentan cinco veces el riesgo de 煤lceras g谩stricas.
- El candidato a f谩rmaco ART26.12 mostr贸 una eficacia comparable al naproxeno en el tratamiento del dolor de osteoartritis
- No se observ贸 desarrollo de tolerancia durante el per铆odo de dosificaci贸n cr贸nica de cuatro semanas
- Potenciales ventajas de seguridad sobre los AINE, que causan efectos secundarios en el 33% de los pacientes
- Efecto directo demostrado sobre los niveles plasm谩ticos relevantes de endocannabinoides
Artelo Biosciences (雮橃姢雼�: ARTL)電� 鞝�35須� 甑牅 旃鸽倶牍勲吀鞚措摐 鞐瓣惮頃欗殞 鞐半 鞁彫歆�鞐勳棎靹� 欤检殧 FABP5 鞏奠牅鞝滌澑 ART26.12鞚� 旮嶌爼鞝侅澑 鞝勳瀯靸� 雿办澊韯半ゼ 氚滍憸頄堨姷雼堧嫟. 氤� 鞐瓣惮電� 觳� 氩堨Ц 韥措灅鞀れ澊鞛� 牍勳槫頂检槫鞚措摐, 牍勳姢韰岆鞚措摐靹� 歆勴喌鞝� 頉勲炒氍检鞚� ART26.12臧� 鞝勳瀯靸� 氇嵏鞐愳劀 瓿磤鞝堨椉 韱奠鞚� 須臣鞝侅溂搿� 臧愳唽鞁滍偍雼る姅 瓴冹潉 鞛呾頄堨姷雼堧嫟.
欤检殧 瓴瓣臣電� ART26.12鞚� 須姤鞚� 鞚茧皹鞝侅澑 NSAID鞚� 雮橅攧搿濎劶瓿� 霃欕摫頃�鞚� 氤挫棳欤检棃鞙茧┌, 4欤缄皠鞚� 毵岇劚 韴棳 旮瓣皠 霃欖晥 雮挫劚鞚� 靸濌赴歆� 鞎婈碃 須臣臧� 鞙犾霅橃棃鞀惦媹雼�. 鞚� 鞎诫鞚� 順堨灔 雮� 鞐旊弰旃鸽倶牍勲吀鞚措摐 2-AG鞕� OEA 靾橃箻毳� 歃濌皜鞁滌紲, 鞓來枼鞚� 氚涭潃 靷鞚� 觳挫 攵�頃� 電ル牓 頄レ儊瓿� 鞐瓣磤鞚� 鞛堨棃鞀惦媹雼�. 韸鬼瀳 ART26.12電� 鞚茧皹鞝侅溂搿� 頇橃瀽鞚� 3攵勳潣 1鞐愳劀 鞙勳灔 攵�鞛戩毄鞚� 鞚检溂韨り碃 鞙勱钉鞏� 鞙勴棙鞚� 5氚� 歃濌皜鞁滍偆電� NSAID鞐� 牍勴暣 鞎堨爠靹� 氅挫棎靹� 鞚挫爯鞚� 鞝滉车頃� 靾� 鞛堨姷雼堧嫟.
- 鞎诫 頉勲炒 ART26.12臧� 瓿磤鞝堨椉 韱奠 旃橂鞐愳劀 雮橅攧搿濎劶瓿� 鞙犾偓頃� 須姤鞚� 氤挫瀯
- 4欤缄皠 毵岇劚 韴棳 旮瓣皠 霃欖晥 雮挫劚 氚滍槃鞚� 甏�彀半悩歆� 鞎婌潓
- 頇橃瀽鞚� 33%鞐愳劀 攵�鞛戩毄鞚� 鞚检溂韨る姅 NSAID鞐� 牍勴暣 鞛犾灛鞝� 鞎堨爠靹� 鞚挫爯
- 甏�霠� 鞐旊弰旃鸽倶牍勲吀鞚措摐 順堨灔 靾橃箻鞐� 雽�頃� 歆侅爲鞝侅澑 須臣 鞛呾
Artelo Biosciences (Nasdaq : ARTL) a pr茅sent茅 des donn茅es pr茅cliniques positives pour son principal inhibiteur FABP5, ART26.12, lors du 35e Symposium annuel international de la Soci茅t茅 de recherche sur les cannabino茂des. L鈥櫭﹖ude a d茅montr茅 qu鈥橝RT26.12, un candidat m茅dicament analg茅sique de premi猫re classe, non opio茂de et non st茅ro茂dien, r茅duisait efficacement la douleur li茅e 脿 l鈥檃rthrose dans des mod猫les pr茅cliniques.
Les r茅sultats cl茅s ont montr茅 que l鈥檈fficacit茅 d鈥橝RT26.12 茅tait comparable 脿 celle du naprox猫ne, un AINS courant, tout en maintenant son efficacit茅 sur une p茅riode de traitement chronique de quatre semaines sans d茅velopper de tol茅rance. Le m茅dicament a augment茅 les niveaux plasmatiques des endocannabino茂des 2-AG et OEA, ce qui a 茅t茅 corr茅l茅 脿 une meilleure capacit茅 de charge des membres affect茅s. Il est important de noter qu鈥橝RT26.12 pourrait offrir des avantages en mati猫re de s茅curit茅 par rapport aux AINS, qui provoquent g茅n茅ralement des effets gastro-intestinaux chez un tiers des patients et augmentent par cinq le risque d鈥檜lc猫res gastriques.
- Le candidat m茅dicament ART26.12 a montr茅 une efficacit茅 comparable au naprox猫ne dans le traitement de la douleur li茅e 脿 l鈥檃rthrose
- Aucune tol茅rance d茅velopp茅e lors de la p茅riode de traitement chronique de quatre semaines
- Avantages potentiels en mati猫re de s茅curit茅 par rapport aux AINS, qui causent des effets secondaires chez 33 % des patients
- Effet direct d茅montr茅 sur les niveaux plasmatiques pertinents d鈥檈ndocannabino茂des
Artelo Biosciences (Nasdaq: ARTL) pr盲sentierte positive pr盲klinische Daten f眉r seinen f眉hrenden FABP5-Inhibitor ART26.12 auf dem 35. Jahrestreffen der Internationalen Cannabinoid-Forschungsgesellschaft. Die Studie zeigte, dass ART26.12, ein neuartiger, nicht-opioider, nicht-steroidaler Analgetikum-Kandidat, in pr盲klinischen Modellen effektiv Arthrose-Schmerzen reduzierte.
Die wichtigsten Erkenntnisse zeigten, dass die Wirksamkeit von ART26.12 mit der von Naproxen, einem g盲ngigen NSAR, vergleichbar ist, wobei die Wirksamkeit 眉ber einen vierw枚chigen chronischen Dosierungszeitraum ohne Toleranzentwicklung erhalten blieb. Das Medikament erh枚hte die Plasmaspiegel der Endocannabinoide 2-AG und OEA, was mit einer verbesserten Belastungsf盲higkeit der betroffenen Gliedma脽en korrelierte. Wichtig ist, dass ART26.12 Sicherheitsvorteile gegen眉ber NSAR bieten k枚nnte, die typischerweise bei einem Drittel der Patienten gastrointestinale Nebenwirkungen verursachen und das Risiko f眉r Magengeschw眉re verf眉nffachen.
- Der Arzneimittelkandidat ART26.12 zeigte eine vergleichbare Wirksamkeit wie Naproxen bei der Behandlung von Arthrose-Schmerzen
- Keine Toleranzentwicklung w盲hrend des vierw枚chigen chronischen Dosierungszeitraums beobachtet
- Potenzielle Sicherheitsvorteile gegen眉ber NSAR, die bei 33 % der Patienten Nebenwirkungen verursachen
- Nachgewiesene direkte Wirkung auf relevante Endocannabinoid-Plasmaspiegel
- None.
- Still in preclinical stage, requiring further clinical trials before potential commercialization
Insights
Artelo's ART26.12 shows promising preclinical results for osteoarthritis pain with sustained efficacy and potential NSAID safety advantages.
Artelo Biosciences has presented compelling preclinical data for their lead FABP5 inhibitor ART26.12 in an osteoarthritis pain model at the International Cannabinoid Research Society Symposium. The results reveal several notable advantages over current treatment options that investors should understand.
The data demonstrates that ART26.12 achieves pain relief comparable to naproxen, a widely-used NSAID, but with a crucial difference: ART26.12 maintained its efficacy throughout four weeks of chronic dosing without developing tolerance. This is particularly significant for chronic pain conditions like osteoarthritis that require long-term management.
The mechanism of action involves increasing plasma levels of endocannabinoids (2-AG and OEA), which correlated positively with improved weight-bearing capacity on affected limbs. This novel approach represents a first-in-class, non-opioid, non-steroidal analgesic with potential market differentiation.
From a commercial perspective, ART26.12 could address significant limitations of current NSAIDs, which cause gastrointestinal side effects in approximately
This preclinical data builds upon recently announced positive human single-dose safety data, suggesting Artelo is methodically advancing through early development stages. However, investors should recognize that significant clinical hurdles remain before commercialization is possible.
ART26.12, a Novel FABP5 Inhibitor, Demonstrates Sustained Analgesic Effects Without Tolerance
SOLANA BEACH, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced the presentation of preclinical data in an osteaoarthritis (OA) pain model on its lead fatty acid binding protein 5 (FABP5) inhibitor, ART26.12, at the , being held July 6鈥�10 in Bloomington, Indiana.
The presentation, titled 鈥淭he Fatty Acid Binding Protein 5 Inhibitor ART26.12 Alleviates Osteoarthritis Pain,鈥� was delivered on July 8th by Dr. Martin Kaczocha, Assistant Professor in the Departments of Anesthesiology, Biochemistry and Cell Biology at Stony Brook University, New York.聽Dr. Kaczocha was the lead researcher for the OA study and serves as a scientific advisor at Artelo. The results demonstrated that ART26.12, a first-in-class, non-opioid, non-steroidal analgesic drug candidate, significantly alleviated pain associated with OA in preclinical models, in which a direct effect on plasma levels of relevant endocannabinoids was also observed.
鈥淲e are grateful to continue our translational research with ART26.12 in OA models in collaboration with Stony Brook University,鈥� commented Professor Saoirse O鈥橲ullivan, Vice President of Translation Sciences at Artelo. 鈥淥ur latest data now shows in this OA model that daily treatment with ART26.12 leads to increases in plasma levels of the endocannabinoids 2-Arachidonoylglycerol (2-AG) and Oleoylethanolamide (OEA). Both of these endocannabinoids were positively correlated with pain ratings such that high levels of plasma 2-AG and OEA were associated with an increased ability of the animals to bear weight on the operated limb.鈥�
In these OA studies with ART26.12, the FABP5 inhibitor demonstrated efficacy comparable to naproxen, a commonly prescribed nonsteroidal anti-inflammatory drug (NSAID), with ART26.12 maintaining analgesic efficacy throughout a four-week period of chronic dosing. Importantly, this extended administration did not result in the development of tolerance or diminished activity, a positive attribute that supports ART26.12鈥檚 potential in long-term treatment scenarios.
From a safety perspective, ART26.12 may offer advantages over NSAIDs, which are collectively associated with gastrointestinal side effects in approximately one-third of patients receiving NSAIDs and are linked to a five-fold increase in gastric ulcer complications. ART26.12鈥檚 distinct pharmacological profile and utilization of endocannabinoids has the potential to provide a more favorable therapeutic option for patients requiring ongoing pain relief.
鈥淭hese preclinical OA study results, which complement our recently announced positive human single dose safety data, continue to support ART26.12 as a well-differentiated and potentially safer alternative to NSAIDs in the treatment of osteoarthritis pain. We look forward to advancing our lead FABP5 inhibitor program through clinical development,鈥� concluded Professor O鈥橲ullivan.
About ART26.12
ART26.12, Artelo鈥檚 lead FABP5 inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The initial clinical development planned is for chemotherapy-induced peripheral neuropathy (CIPN). FABPs are a family of intracellular proteins that chaperone lipids important to normal cellular function. FABP is overexpressed and associated with abnormal lipid signaling in several pathologies. In addition to ART26.12 in CIPN, Artelo鈥檚 extensive library of small molecule inhibitors of FABPs has shown therapeutic promise for the treatment of certain cancers, neuropathic and nociceptive pain, anxiety disorders, and psoriasis. ART26.12 has been included in Helping to End Addiction Long-term庐 (HEAL) Initiative鈥檚 Preclinical Screening Platform for Pain program of the U.S. National Institutes of Health. The HEAL program is dedicated to advancing non-opioid solutions to pain and curbing opioid use disorder.
About Artelo Biosciences
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the Company applies leading-edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and X: @ArteloBio.
About the International Cannabinoid Research Society
The聽International Cannabinoid Research Society聽(ICRS) is the premier global scientific association with more than 650 international members from 40 countries, all active researchers in the field of endogenous, plant-derived, and synthetic cannabinoids and related bioactive lipids. In addition to acting as a source for impartial information on cannabis and the cannabinoids, the main role of the ICRS is to provide an open forum for researchers to meet and discuss their research. Dr.鈥檚 O鈥橲ullivan and Kaczocha were awarded the prestigious Early Career Award (formerly the Young Investigator of the Year) at the annual ICRS Symposium in 2016 and 2017, respectively. Since that time Artelo has been the exclusive underwriter of the Award at the ICRS. The ICRS Symposium is being held July 6-10, 2025 in Bloomington, IN. Interested parties may follow聽聽on X.聽
About Osteoarthritis
Osteoarthritis (OA) is a progressive joint disease in which cartilage wears away over time, causing chronic pain, stiffness, swelling, and significant loss of mobility, especially in the knees, hips, hands, and spine. OA affects approximately 606.9 million people globally, including over 32 million in the U.S., and can lead to disabling pain, reduced quality of life, and loss of independence, especially in advanced cases. OA is often treated with over the counter and prescription drugs commonly used for pain and inflammation, including NSAIDs, acetaminophen, corticosteroids, duloxetine, and opioids. Intermittent hyaluronic acid injections may offer relief for some individuals over the long term.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company鈥檚 future investment policy of its excess capital, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management鈥檚 current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, 鈥渆xpect,鈥� 鈥渁nticipate,鈥� 鈥渋ntend,鈥� 鈥減lan,鈥� 鈥渂elieve,鈥� 鈥渆stimate,鈥� 鈥減otential,鈥� 鈥減redict,鈥� 鈥減roject,鈥� 鈥渟hould,鈥� 鈥渨ould鈥� and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company鈥檚 filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.
Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
贰尘补颈濒:听
FAQ
What are the key findings of Artelo Biosciences' (ARTL) ART26.12 preclinical trial for osteoarthritis?
How does Artelo's ART26.12 compare to traditional NSAIDs for osteoarthritis treatment?
What makes Artelo's ART26.12 different from other pain medications?
What is the current development stage of Artelo's (ARTL) ART26.12?
How long did the ART26.12 osteoarthritis study last?
